Ependymoma accounts for 8% to 10% of all childhood central nervous system (CNS) tumors, with fewer than 170 new cases diagnosed annually in the United States in children and adults younger than 25 years old. The mean age at the time of diagnosis ranges from 51 to 71 months,[2-5] and 25% to 40% of those diagnosed are younger than age 3. Survival statistics for ependymoma are generally disappointing: The historical 5-year survival estimate is 50% to 64%, and the historical progression-free survival estimate is 23% to 45%.[2,4,7-9] Recurrences are typically local, and the median time to recurrence is 13 to 25 months.[2-4,7,9,10] Approximately 20% of failures involve distant recurrence, and late recurrences are not uncommon.
Ependymoma develops from the neuroepithelial lining of the ventricles of the brain and the central canal of the spinal cord; 90% of tumors are located intracranially, with 30% occurring above the tentorium and 60% below it (Figure 1). Supratentorial ependymoma arises either from the lateral or third ventricle (60%) or from the cerebral hemisphere (40%).[1,11] Infratentorial ependymoma arises from one of three specific sites within the fourth ventricle: the floor (60%), the lateral aspect (30%), or the roof (10%).[12,13] Tumors that arise from the floor of the fourth ventricle may extend through the foramen of Magendie and over the dorsal surface of the spinal cord. Those that arise from the lateral aspect of the fourth ventricle can extend out of the foramen of Luschka and into the cerebellopontine angle and along the anterior aspect of the pons and medulla (Figure 2).
Complete surgical removal of posterior fossa ependymoma arising from the floor or lateral aspect of the fourth ventricle is difficult because these tumors are typically close to the surface of the brainstem and cranial nerves. Fortunately, neuraxis dissemination at the time of diagnosis is rare and occurs in fewer than 7% of patients (Figure 3).
Numerous studies have sought to identify prognostic factors for intracranial ependymoma; most have been single-institution, retrospective reports that span several decades and consequently include numerous advances in neuroimaging, neurosurgery, radiation oncology, chemotherapy, and supportive measures. Surgical resection appears to be the most important prognostic factor.[2-5,7-11,14] In patients with completely resected tumors, the 5-year survival estimate is 67% to 80% and the 5-year progression-free survival estimate is 51% to 75%. Among patients with incompletely resected tumors, the 5-year survival estimate is 22% to 47%, and the 5-year progression-free survival estimate is 0% to 26% (Figure 4).
Age at Diagnosis
Age, at the time of diagnosis, may also be an important prognostic factor. Very young children typically have a poorer outcome.[4,7,15] For children younger than 3 years old at diagnosis, Pollack et al reported a 5-year survival estimate of 22% and a progression-free survival estimate of 12%. In older children, the 5-year survival estimate is 75%, and the progression-free survival estimate is 60%.
Duffner et al reported the experience of the Pediatric Oncology Group (POG) in very young children. For children who were younger than age 3 and had undergone gross total resection, they calculated a 5-year survival rate of 61%, whereas for those who had undergone subtotal resection, the estimate was 30%. The POG study also showed a 63% 5-year survival for young children (aged 24 to 35 months) in whom radiation therapy was delayed for 1 year, but a 26% 5-year survival for infants and very young children (aged 0 to 23 months) in whom radiation therapy was delayed for 2 years. The POG findings suggest that the poor survival estimates frequently reported for very young children are most likely related to the higher incidence of infratentorial tumors, the lower rate of complete resection, and the delay in the administration of radiation therapy.
Historic studies have shown that patients with ependymoma who receive radiation therapy experience a better outcome than those who are not treated with irradiation.[17,18] In addition, one study suggested that the improvement in outcome may be radiation dose-dependent (ie, higher doses may improve outcome). However, no randomized trials have unequivocally demonstrated that improved outcome is caused solely by radiation therapy; other factors such as extent of resection and age at the time of diagnosis also contribute to the outcome.
Histologic Grade of the Tumor
One of the most controversial prognostic factors in childhood ependymoma is the histologic grade of the tumor. Although numerous reports have suggested that patients with differentiated ependymoma achieve a better outcome than do those with anaplastic ependymoma,[11,17,20-25] some investigators believe that histologic grade has no prognostic significance.
We recently reported histologic characterization of tumors and outcome in a contemporary series of 50 patients. In a blinded review of pathology, we determined that histologic grade was significantly related to progression-free survival after irradiation (P < .001). The 2-year event-free survival estimate (± SE) was 32% ± 14% for patients with anaplastic ependymoma and 84% ± 7% for patients with differentiated ependymoma. Statistical significance was maintained when the analysis was adjusted for age (< 3 years), chemotherapy with or without tumor progression before radiation therapy, and extent of resection.
The finding of a poor progression-free survival estimate after irradiation for patients with anaplastic ependymoma parallels the findings from other contemporary series.[19,24] Data from the blinded pathology review at St. Jude also showed that anaplastic ependymoma was more likely to occur in the supratentorial brain (P = .002). Of 12 patients with supratentorial tumor, 6 experienced a recurrence despite gross total resection and irradiation.
Histologic evaluation plays an important role in the design and interpretation of prospective trials and in determining the significance of prognostic factors in the current treatment era (Figure 5). Cooperative multi-institutional protocols will enable us to determine the significance of the various factors that will be used to estimate prognosis and stratify individual treatments.
1. Ries LAG et al: Cancer Statistics Review, 1973-1997. National Cancer Institute, Bethesda, Md, 2000.
2. Foreman NK, Love S, Thorne R: Intracranial ependymomas: Analysis of prognostic factors in a population-based series. Pediatr Neurosurg 24:119-125, 1996.
3. Perilongo G, Massimino M, Sotti G, et al: Analyses of prognostic factors in a retrospective review of 92 children with ependymoma: Italian Pediatric Neuro-oncology Group. Med Pediatr Oncol 29:79-85, 1997.
4. Horn B, Heideman R, Geyer R, et al: A multi-institutional retrospective study of intracranial ependymoma in children: Identification of risk factors. J Pediatr Hematol Oncol 21:203-211, 1999.
5. Sutton LN, Goldwein J, Perilongo G, et al: Prognostic factors in childhood ependymomas. Pediatr Neurosurg 16:57-65, 1990-1991.
6. Evans AE, Anderson JR, Lefkowitz-Boudreaux IB, et al: Adjuvant chemotherapy of childhood posterior fossa ependymomas: Craniospinal irradiation with or without adjuvant CCNU, vincristine, and presdnisone: A Children’s Cancer Group study. Med Pediatr Oncol 27:8-14, 1996.
7. Pollack IF, Gerszten PC, Martinez AJ, et al: Intracranial ependymomas of childhood: Long-term outcome and prognostic factors. Neurosurg 37:655-666, 1995.
8. Rousseau P, Habrand J, Sarrazin D, et al: Treatment of intracranial ependymomas of children: Review of a 15-year experience. Int J Radiat Biol Phys 28:381-386, 1994.
9. Robertson PL, Zeltzer PM, Boyett JM, et al: Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: A report of the Children’s Cancer Group. J Neurosurg 88:695-703, 1998.
10. Needle MN, Goldwein JW, Grass J, et al: Adjuvant chemotherapy for the treatment of intracranial ependymoma of childhood. Cancer 80:341-347, 1997.
11. Nazar GB, Hoffman HJ, Becker LE, et al: Infratentorial ependymomas in childhood: Prognostic factors and treatment. J Neurosurg 72:408-417, 1990.
12. Ikezaki K, Matsushima T, Inoue T, et al: Correlation of microanatomical localization with postoperative survival in posterior fossa ependymomas. Neurosurgery 32:38-44, 1993.
13. Sanford RA, Gajjar A: Ependymomas. Clin Neurosurg 44:559-570, 1997.
14. Healey EA, Barnes PD, Kupsky WJ, et al: The prognostic significance of postoperative residual tumor in ependymoma. Neurosurgery 28:666-671, 1991.
15. Sala F, Talacchi A, Mazza C, et al: Prognostic factors in childhood intracranial ependymomas. Pediatr Neurosurg 28:135-142, 1998.
16. Duffner PK, Krischer JP, Sanford RA, et al: Prognostic factors in infants and very young children with intracranial ependymomas. Pediatr Neurosurg 28:215-222, 1998.
17. Mork SJ, Loken AC: Ependymoma: A follow-up study of 101 cases. Cancer 40:907-915, 1977.
18. Shuman RM, Alvord EC, Leech RW: The biology of childhood ependymomas. Arch Neurol 32:731-739, 1975.
19. Merchant TE, Haida T, Wang MH, et al: Anaplastic ependymoma: Treatment of pediatric patients with or without craniospinal radiation therapy. J Neurosurg 86:943-949, 1997.
20. Pierre-Kahn A, Hirsch JF, Roux FX, et al: Intracranial ependymomas in childhood. Survival and functional results of 47 cases. Childs Brain 10:145-156, 1983.
21. Shaw EG, Evans RG, Scheithauer BW, et al: Postoperative radiotherapy of intracranial ependymoma in pediatric and adult patients. Int J Radiat Oncol Biol Phys 13:1457-1462, 1987.
22. Kovnar E, Kun L, Burger P, et al: Patterns of dissemination and recurrence in childhood ependymoma: Preliminary results of Pediatric Oncology Group Protocol #8532. Ann Neurol 30:457, 1991.
23. Kovalic JJ, Flaris N, Grigsby PW, et al: Intracranial ependymoma long-term outcome, patterns of failure. J Neurooncol 15:125-131, 1993.
24. Timmermann B, Kortmann RD, Kuhl J, et al: Combined postoperative irradiation and chemotherapy for anaplastic ependymoma in childhood: Results of the German Prospective Trials Hit ’88/’89 and Hit ’91 (abstract 122). Int J Radiat Oncol Biol Phys 42(suppl 1):185, 1998.
25. Merchant TE, Jenkins JJ, Burger PC, et al: The influence of histology on the time to progression after irradiation for localized ependymoma in children. Int J Radiat Oncol Biol Phys. In press.
26. Hukin J, Epstein F, Lefton D, et al: Treatment of intracranial ependymoma by surgery alone. Pediatr Neurosurg 29:40-45, 1998.
27. Palma L, Celli P, Mariottini A, et al: The importance of surgery in supratentorial ependymomas. Long-term survival in a series of 23 cases. Childs Nerv Syst 16:170-175, 2000.
28. Foreman NK, Love S, Gill SS, et al: Second-look surgery for incompletely resected fourth ventricle ependymomas: Technical case report. Neurosurgery 40:856-860, 1997.
29. Sanford RA, Kun LE, Heideman RL, et al: Cerebellar pontine angle ependymoma in infants. Pediatr Neurosurg 27:84-91, 1997.
30. Osterdock RJ, Sanford RA, Merchant TE: Pediatric ependymoma (40 in 36 months). Paper presented at the annual meeting of American Association of Neurosurgeons (AANS)/Central Nervous System (CNS) Section on Pediatric Neurological Surgery; December 6-9, 2000; Coronado, California.
31. Kovnar E, Curran W, Tomita, et al: Hyperfractionated irradiation for childhood ependymoma: Improved local control in subtotally resected tumors (abstract). Childs Nerv Syst 14:489, 1998.
32. Vanuytsel LJ, Bessell EM, Ashley SE, et al: Intracranial ependymoma: Long-term results of a policy of surgery and radiotherapy. Int J Radiat Oncol Biol Phys 23:313-319, 1992.
33. Merchant TE, Zhu Y, Thompson SJ, et al: Preliminary results from a phase II trial of conformal radiation therapy for localized pediatric brain tumors. Int J Radiol Oncol Biol Phys 52:325-332, 2002.
34. Merchant TE, Smith JM, Williams T, et al: Pre-irradiation endocrinopathies in pediatric patients determined by dynamic tests of endocrine function. Paper presented at the 6th International Conference on the Long-Term Complications of Treatment of Children and Adolescents for Cancer; June 23-24, 2000; Niagara-on-the-Lake, Ontario, Canada.
35. Merchant TE, Goloubeva O, Kiehna EN, et al: Neurocognitive effects of radiation therapy. 43rd Annual Meeting of the American Society of Therapeutic Radiology and Oncology. San Francisco, Nov 4-8, 2001.
36. Merchant TE, Smith JM, Williams T, et al: Pre-irradiation endocrinopathies in pediatric patients determined by dynamic tests of endocrine function. Sixth International Conference on the Long-Term Complications of Treatment of Children and Adolescents for Cancer. Niagara-on-the-Lake, Ontario, Canada, June 23-24, 2000.
37. Merchant TE, Goloubeva O, Pritchard DL, et al: Radiation dose-volume effects on growthy hormone secretion. Int J Radiat Oncol Biol Phys 52:1264-1270, 2002.
38. Ris MD, Packer R, Goldwein J, et al: Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: A Children’s Cancer Group study. J Clin Oncol 19(15):3470-3476, 2001.
39. Walter AW, Mulhern RK, Gajjar A, et al: Survival and neurodevelopmental outcome of young children with medulloblastoma at St. Jude Children’s Research Hospital. J Clin Oncol 17(12):3720-3728, 1999.
40. Chiu JK, Woo SY, Ater J, et al: Intracranial ependymoma in children: Analysis of prognostic factors. J Neurooncol 13:283-290, 1992.
41. Bouffet E, Perilongo G, Canete A, et al: Intracranial ependymomas in children: A critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol 30:319-331, 1998.
42. White L, Kellie S, Gray E, et al: Postoperative chemotherapy in children less than 4 years of age with malignant brain tumors: Promising initial response to a VETOPEC-based regimen. A study of the Australian and New Zealand Children’s Cancer Study Group (ANZCCSG). J Pediatr Hematol Oncol 20:125-130, 1998.
43. Duffner PK, Horowitz ME, Krischer JP, et al: Postoperative chemotherapy and delayed radiation in children less than 3 years of age with malignant brain tumors. N Engl J Med 328:1725-1731, 1993.
44. Mason WP, Grovas A, Halpern S, et al: Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 16:210-221, 1998.
45. Fouladi M, Baruchel S, Chan H, et al: Use of adjuvant ICE chemotherapy in the treatment of anaplastic ependymomas. Childs Nerv Syst 14:590-595, 1998.
46. Strother D, Kepner J, Aronin PA, et al: Dose-intensive chemotherapy prolongs event-free survival for very young children with ependymoma. Results of pediatric oncology group study 9233 (abstract 2302). Proc Am Soc Clin Oncol 19:585a, 2000.
47. Grill J, Le Delay MC, Gambarelli D, et al: Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: A multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol 19:1288-1296, 2001.
48. Gornet MK, Buckner JC, Marks RS, et al: Chemotherapy for advanced CNS ependymoma. J Neurooncol 45:61-67, 1999.
49. Needle MN, Molloy PT, Geyer JR, et al: Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol 29:28-32, 1997.
50. Gaynon PS, Ettinger LJ, Baum ES, et al: Carboplatin in childhood brain tumors: A Children’s Cancer Study Group Phase II trial. Cancer 66:2465-2469, 1990.
51. Cohen BH, Zweidler P, Goldwein JW, et al: Ototoxic effect of cisplatin in children with brain tumors. Pediatr Neurosurg 16:292-296, 1990-1991.